欢迎访问行业研究报告数据库

报告分类

重点报告推荐

当前位置:首页 > 行业导航

找到报告 33861 篇 当前为第 3356 页 共 3387

所属行业:医药制造业

  • 33551.中药民族药成为贵州医药工业主导

    [医药制造业] [2013-06-20]

    关键词:中药;民族药;工业主导
  • 33552.安徽淮南市多措并举促进医药经济快速发展

    [医药制造业] [2013-06-20]

    关键词:医药产业;医药经济;措施
  • 33553.益佰制药溢价56倍购微利资产盈利预测变数大

    [医药制造业] [2013-06-20]

    关键词:益佰制药;百祥制药;收购;盈利预测
  • 33554.中国民企原创药专利首次授权海外顶尖制药集团

    [医药制造业] [2013-06-20]

    关键词:民企;原创药;专利;制药
  • 33555.神威药业4个处方药上市

    [医药制造业] [2013-06-20]

    关键词:神威药业;处方药;上市
  • 33556.医药企业原料药出口市场研究

    [医药制造业] [2013-06-19]

    随着经济实力加强和全球经济一体化的实现,我国原料药的生产和出口比重也越来越大,在世界原料药是市场中占据了举足轻重的地位,是原料药生产和出口的大国。但是,我国原料药的出口仍然要面对很多贸易上的考验和难关,并且,金融危机和全球经济的缓慢复苏也给我国原料药的出口带来了巨大的挑战。本文主要从经济学和国际贸易和管理学的角度出发,主要阐述了我国医药企业原料药的国内外市场现状、市场优势和面临挑战以及应当采取的战略对策。
    关键词:医药企业;原料药;出口市场
  • 33557.亚太报告——药品

    [医药制造业] [2013-06-17]

    In the past six months, drug price cuts continued to reverberate across the Asia-Pacific. Major countries such as China, India and Australia announced further drug price reductions. Leading Asian drugmakers posted a mixed bag of earnings. Takeda Pharmaceutical (TSE: 4502) and Dr Reddy’s Laboratories (BSE: 500124) for example, posted double-digit declines in net profit while others such as Lupin Ltd (NYSE: MYL) saw significant growth as its profits rose more than 40% year-on-year due to strong sales growth in their US market. The shares prices of 11 leading Asian pharmaceutical companies posted average gains of approximately 22% over the six-month period under review from September 4, 2012, to February 26, 2013. Ten out of the 11 companies assessed by Mergent saw their share prices rise over the period, with Dainippon Sumitomo Pharma’s stock price rising the most at nearly 58%. In the past six months, pharmaceutical merger and acquisition activity in the region somewhat slowed down, compared to the strong level of merger and acquisition activity (M&A) seen in the first half of 2012.
    关键词:亚太地区;药品;市场环境;市场趋势
  • 33558.亚太报告——生物科技

    [医药制造业] [2013-06-17]

    The Asia-Pacific biotech industry remained one of the fastest emerging knowledge-based industries in the region over the last six months. Several leading companies reported higher revenues, while an average of the stock prices of companies tracked by Mergent rose 4.07% over the six-month period. Due to economic challenges in several major markets, a steady number of foreign biotech and pharmaceutical companies, particularly from North America and Europe, shifted their focus to markets in the Asia-Pacific. The industry also saw several cross-border mergers and acquisitions (M&A) as biotech companies sought to obtain the benefits of various fiscal incentives in other nations and regions.
    关键词:亚太地区;生物科技;环境;市场展望与趋势
  • 33559.医药汇编——第526期

    [医药制造业] [2013-06-13]

    报告从医药行业安邦视点、政策环境、市场行情、厂商动态、科技研发、国际资讯、行业数据、分析评论等几个方面进行了分析及评论。
    关键词:安邦视点;政策环境;市场行情;厂商动态;科技研发;国际资讯;行业数据;分析评论
  • 33560.医药竞争情报——第448期

    [医药制造业] [2013-06-13]

    报告从医药行业事件分析、竞争环境、竞争对手、行业数据等几个方面进行了分析评论。
    关键词:行业事件分析;竞争环境;竞争对手;行业数据
首页  上一页  ...  3351  3352  3353  3354  3355  3356  3357  3358  3359  3360  ...  下一页  尾页  
© 2016 武汉世讯达文化传播有限责任公司 版权所有
客服中心

QQ咨询


点击这里给我发消息 客服员


电话咨询


027-87841330


微信公众号




展开客服